Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21963700 | 0.88 | KMT2A (0.39) | MEN1KMT2ALMNAGAA | |
| SCHEMBL25707381 | 0.84 | LMNA (0.39) | MEN1KMT2ALMNAGAA | |
| SCHEMBL22010512 | 0.82 | GBA1 (0.34) | MEN1KMT2ALMNAGAA | |
| SCHEMBL24923371 | 0.80 | ESR1 (0.32) | GAA | |
| SCHEMBL22010503 | 0.75 | CA2 (0.43) | EGFRITKMEN1KMT2A | |
| SCHEMBL22010747 | 0.74 | ESR1 (0.38) | KMT2AGAA | |
| Hydrochloric Acid SCHEMBL29958615 | 0.74 | CA2 (0.42) | EGFRITKMEN1KMT2A | |
| SCHEMBL21963733 | 0.74 | KMT2A (0.46) | MEN1KMT2A | |
| SCHEMBL21963701 | 0.73 | TOP2A (0.36) | MEN1KMT2AGAA | |
| SCHEMBL21963732 | 0.70 | SLC1A5 (0.41) | EGFRMEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2026-02-10 | — | — | US | disclosed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| EP-3880675-B1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INT SA (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2023-02-02 | — | — | US | disclosed |
| EP-4077324-A1 | NOVEL COMPOUNDS AND THEIR USE | Debiopharm International SA (CH) | 2022-10-26 | — | — | EP | disclosed |
| EP-3880675-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | Debiopharm International SA (CH) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021123372-A1 | NOVEL COMPOUNDS AND THEIR USE | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020099341-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159519-A1 | NOVEL COMPOUNDS AND THEIR USE | LSS, PGLS, LDHB | EGFR 1199/4885ITK 4340/4885MEN1 4447/4885 |
| US-12545672-B2 | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof | MRPL21, EMG1, RRS1 | EGFR 976/4885ITK 4732/4885MEN1 1541/4885 |
| US-20230035837-A1 | ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF | GMPS, GNE, GANC | EGFR 1692/4885ITK 779/4885MEN1 585/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | EGFR 1320/4885ITK 4492/4885MEN1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.